Olaparib pharmaceutical composition and its preparation, preparation method and use
The preparation of olapani pharmaceutical compositions by using carrier materials such as cyclodextrin and copovidone combined with hot melt extrusion method and adding TPGS, the problem of insufficient solubility and bioavailability of olapani drugs in the gastrointestinal tract is solved. , achieving more efficient therapeutic effects and lower energy consumption production processes.
Patent Information
- Application Number
- CN202010107404.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-02-21
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-02-21
AI Technical Summary
The existing solubility and bioavailability of olapanib preparations in the gastrointestinal tract lead to poor treatment effects, high energy consumption and low efficiency in the production process.
The drug composition of olapani is prepared by combining carrier materials such as cyclodextrin and copovidone with hot melt extrusion method, and the solubilizer such as TPGS is added to the pharmaceutical composition to improve the solubility of olapani in the gastrointestinal tract and Bioavailability while optimizing production processes to reduce energy consumption.
It significantly improves the absorption and bioavailability of olapani in the body, reduces production energy consumption, improves production efficiency, and improves the therapeutic effect by improving solubility and dissolution.
Smart Images

Figure CN113288859B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical preparations, and in particular to a pharmaceutical composition comprising olaparib, and a preparation method and use thereof. Background Art
[0002] The chemical name of Olaparib (also known as Olaparib) is 4-[3-(4-cyclopropanecarboxyl-piperazine-1-carboxyl)-4-fluoro-benzyl]-2H-phenolazine-1-one, and its molecular formula is C 24 H 23 FN4O3, CAS registration number is 763113-22-0, the structural formula is as follows:
[0003]
[0004] Olaparib is a poly(ADP-ribose) polymerase (PARR) inhibitor used for tumor treatment. It has been approved for marketing in the United States, Europe, Japan, and China for the treatment of ovarian cancer, breast cancer, and pancreatic cancer. In addition, related clinical trials are underway for malignant tumors such as prostate cancer, non-small cell lung cancer, esophageal cancer, and gastric cancer.
[0005] CN102238945A discloses a solid dispersion containing olaparib and copolyvidone VA 64, which is prepared by hot melt extrusion. CN104434809A uses povidone instead of copolyvidone as a matrix polymer, discloses solid dispersion particles composed of olaparib, povidone and a lubricant, the hygroscopicity of the composition is lower than that of the comparative example with copolyvidone as a carrier, and the preparation method is hot melt extrusion. CN106692066A discloses a solid dispersion of olaparib, povidone or copolyvidone, which is prepared by hot melt extrusion. Summary of the invention
[0006] In one aspect, the present invention relates to a pharmaceutical composition comprising an active ingredient olaparib and a carrier material cyclodextrin. In one embodiment, the cyclodextrin is selected from one or more of α-cyclodextrin, γ-cyclodextrin, β-cyclodextrin, hydroxypropyl β-cyclodextrin, hydroxypropyl α-cyclodextrin, sulfobutyl β-cyclodextrin, and methyl β-cyclodextrin, preferably hydroxypropyl β-cyclodextrin.
[0007] The pharmaceutical composition of the present invention may further comprise a second carrier material in addition to the carrier material cyclodextrin (also referred to as the "first carrier material").
[0008] Preferably, the second carrier material is one or more selected from copovidone, povidone, polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyoxyethylene, hydroxypropyl methylcellulose and its derivatives, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl cellulose, ethyl cellulose, sodium alginate, acrylic resin, and carbomer; more preferably, the second carrier material is one or more selected from copovidone, polyethylene glycol / vinyl caprolactam / vinyl acetate copolymer, acrylic resin, hydroxypropyl methylcellulose and its derivatives; particularly preferably, the second carrier material is one or more selected from copovidone, polyethylene glycol / vinyl caprolactam / vinyl acetate copolymer.
[0009] In a preferred embodiment, the pharmaceutical composition of the present invention may further comprise a solubilizer, such as polyethylene glycol 1000 vitamin E succinate (TPGS).
[0010] In another aspect, the present invention also relates to a pharmaceutical preparation comprising the pharmaceutical composition of the present invention.
[0011] In yet another aspect, the present invention also relates to use of the pharmaceutical composition or pharmaceutical preparation of the present invention in preparing a drug for treating malignant tumors or related diseases.
[0012] In another aspect, the present invention also relates to a method for treating malignant tumors or related diseases, which comprises administering the pharmaceutical composition or pharmaceutical preparation of the present invention to an individual in need thereof.
[0013] The pharmaceutical composition or pharmaceutical preparation of the present invention can be used to treat malignant tumors or related diseases.
[0014] The malignant tumor or related disease includes, but is not limited to, ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, non-small cell lung cancer, esophageal cancer or gastric cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Olaparib-hydroxypropyl beta-cyclodextrin (Kleptose) and / or Tg values corresponding to different Kleptose contents in the pharmaceutical composition made of VA64 carrier.
[0016] Figure 2 Indicates Olaparib-Kleptose and / or XRPD pattern of the pharmaceutical composition made with VA64 carrier.
[0017] Figure 3 Indicates Olaparib-Kleptose and / or Dissolution curves of drug composition 2-3 prepared with VA64 mixed carrier and olaparib API in pH 6.8 buffer.
[0018] Figure 4 Indicates Olaparib-Kleptose and / or The solubility of the olaparib composition corresponding to different Kleptose contents in the pharmaceutical composition made of VA64 mixed carrier (the weight ratio of olaparib to carrier material is 1:2.3) in pH 6.8 buffer.
[0019] Figure 5 Indicates Olaparib-Kleptose and / or The average blood concentration-time curves of Olaparib after the compositions 2-1 and 2-3 made of VA64 vector were administered to human subjects under fasting conditions. DETAILED DESCRIPTION
[0020] General Definition
[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those skilled in the art to which the present invention belongs. If there is a contradiction, the definition provided herein shall prevail. When a certain amount, concentration or other value or parameter is expressed in the form of a range, a preferred range or a preferred upper numerical limit and a preferred lower numerical limit, it should be understood that it is equivalent to specifically revealing any range by combining any pair of upper range limits or preferred values with any lower range limit or preferred values, without considering whether the scope is specifically disclosed. Unless otherwise noted, the numerical range listed herein is intended to include the endpoints of the range, and all integers and fractions within the range.
[0022] The terms "about" and "approximately" when used with a numerical variable generally refer to the value of that variable and all values of that variable are within experimental error (e.g., within a 95% confidence interval for the mean) or within ±10% of the specified value, or a wider range.
[0023] The term "stoichiometric ratio" refers to the mixing of various substances at a certain weight ratio. For example, in the present invention, the active ingredient (such as olaparib) is mixed with the carrier material and the optional pharmaceutically acceptable pharmaceutical excipients at a specified weight ratio.
[0024] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes both the occurrence of said event or circumstance and the non-occurrence of said event or circumstance.
[0025] The expression "comprising" or its synonymous similar expressions "including", "containing" and "having" etc. are open-ended and do not exclude additional unrecited elements, steps or ingredients. The expression "consisting of excludes any element, step or ingredient not specified. The expression "consisting essentially of means that the scope is limited to the specified elements, steps or ingredients, plus the optional presence of elements, steps or ingredients that do not materially affect the basic and novel characteristics of the claimed subject matter. It should be understood that the expression "comprising" "covers the expressions "consisting essentially of" and "consisting of".
[0026] The term "one or more species" may mean 1, 2, 3, 4, 5, 6, 7, 8, 9 or more species.
[0027] The term "pharmaceutically acceptable" refers to a substance that is, within the scope of normal medical judgment, suitable for contact with the tissues of patients without undue toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit-risk ratio, and effective for its intended use.
[0028] The term "pharmaceutical composition" refers to a substance composed of one or more active ingredients, a carrier material, and optionally one or more pharmaceutically acceptable pharmaceutical excipients. In the present invention, it can be referred to as a composition, for example, pharmaceutical composition 1-1 can be referred to as composition 1-1.
[0029] The term "blank composition" refers to a composition that, relative to a pharmaceutical composition, does not contain an active ingredient but only contains carrier materials and optionally other pharmaceutically acceptable excipients.
[0030] The terms "pharmaceutical product", "pharmaceutical dosage form", "dosage form", "pharmaceutical preparation" and the like refer to a pharmaceutical composition administered to a patient in need of treatment, which can generally be in the following forms: powder, granules, pills, capsules, tablets, solutions, suspensions or patches, etc.
[0031] The term "dispersed at the molecular level" means that the drug is dispersed in the carrier material to form a single-phase pharmaceutical composition. In the present invention, the term means that Olaparib is dispersed in the carrier material to form a single-phase pharmaceutical composition (also called a solid solution, dispersion or solid dispersion), and the Tg value of the resulting Olaparib pharmaceutical composition is different from the Tg values of the carrier material and the Olaparib drug substance.
[0032] The terms "dissolved in", "dispersed at the molecular level", "dispersion", "solid solution", "solid dispersion" are used herein as convenient to describe the pharmaceutical compositions of the present invention at various stages of preparation and at various temperatures.
[0033] The term "bioavailability" refers to the extent to which a drug or other substance is available to the body after administration.
[0034] The term “time to peak plasma drug concentration (T max )” refers to the peak plasma drug concentration (C max ) time.
[0035] The term "peak plasma drug concentration (C max )” refers to the maximum plasma drug concentration achieved after administration of the drug.
[0036] The term "AUC 0-∞ ” refers to the area under the plasma drug concentration versus time curve from 0 to infinity after drug administration; while the term “AUC 0-t ” refers to the area under the curve of the plasma drug concentration versus time curve from time 0 to t after drug administration.
[0037] "Ratio A" herein refers to the weight ratio of the active ingredient to the carrier material cyclodextrin (first carrier material) in the composition or formulation, and its calculation method is based on the active ingredient. "Ratio B" herein refers to the weight ratio of the active ingredient to the second carrier material in the composition or formulation, and its calculation method is based on the active ingredient.
[0038] "C%" herein means the weight percentage of the first carrier material to the sum of the first carrier material and the second carrier. For example, "C%" can be expressed as "cyclodextrin / (cyclodextrin+second carrier) %, and a specific example is Kleptose / (Kleptose+ VA64)%.
[0039] Unless otherwise indicated, all percentages, parts, ratios, etc. herein are by weight.
[0040] Pharmaceutical composition and pharmaceutical preparation thereof
[0041] In one aspect, the present invention relates to a pharmaceutical composition comprising an active ingredient Olaparib and a carrier material cyclodextrin. When referring to the active ingredient Olaparib, other pharmaceutically acceptable forms thereof are also covered, including but not limited to pharmaceutically acceptable salts, esters, solvates (such as hydrates), derivatives, etc. It should be understood by those skilled in the art that when calculating Olaparib in a composition or formulation, other forms of Olaparib (if any) should be converted to their corresponding free forms.
[0042] In one embodiment, the cyclodextrin is one or more selected from α-cyclodextrin, γ-cyclodextrin, β-cyclodextrin, hydroxypropyl β-cyclodextrin, hydroxypropyl α-cyclodextrin, sulfobutyl β-cyclodextrin, and methyl cyclodextrin.
[0043] In a preferred embodiment, the cyclodextrin is hydroxypropyl beta-cyclodextrin. An example that can be used is Kleptose, a commercial product of Roquette, France, but it is not limited thereto.
[0044] In one embodiment, the weight ratio (A) of the active ingredient Olaparib to the carrier material cyclodextrin is about 1:0.5-about 1:5, preferably about 1:0.5-about 1:4, and more preferably about 1:0.5-about 1:3; for example, including but not limited to about 1:0.6, about 1:0.7 about 1:0.8, about 1:0.9, about 1:1, about 1:1.2, about 1:1.3, about 1:1.4, about 1:1.5, about 1:1.6, about 1:1.8, about 1:2.0, about 1:2.2, about 1:2.3, about 1:2.4, about 1:2.6, about 1:2.8, about 1:3, etc., and a range consisting of any two of these ratios (values).
[0045] In one embodiment, in addition to the carrier material cyclodextrin, the pharmaceutical composition may further comprise a second carrier material. It will be appreciated by those skilled in the art that the "second" carrier material referred to is only to distinguish it from the carrier material cyclodextrin (also referred to as "first carrier material" or "first carrier material cyclodextrin"), and is not distinguished in nature, use or sequence, etc. In a preferred embodiment, the second carrier material is selected from copolyvidone, povidone, polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, polyoxyethylene, hydroxypropyl methylcellulose and its derivatives, hydroxypropyl cellulose, methylcellulose, hydroxyethyl cellulose, ethyl cellulose, sodium alginate, acrylic resin, and one or more of carbomer.
[0046] In a preferred embodiment, the second carrier material is one or more selected from copovidone, polyethylene glycol / vinyl caprolactam / vinyl acetate copolymer, acrylic resin, hypromellose and derivatives thereof.
[0047] In a more preferred embodiment, the second carrier material is one or more selected from copovidone, polyethylene glycol / vinyl caprolactam / vinyl acetate copolymer.
[0048] In a specific embodiment, the second carrier material is a polyethylene glycol / vinyl caprolactam / vinyl acetate copolymer. Examples of commercially available products from BASF include But it is not limited to this.
[0049] In a preferred embodiment, the second carrier material is copolyvidone. Examples of products that can be used include the commercially available product VA64 or Ashland Plasdone TM S630, but not limited thereto.
[0050] In one embodiment, the weight ratio of the active ingredient Olaparib to the second carrier material (B) is about 1:0.5-about 1:5, preferably about 1:0.5-about 1:3, and more preferably about 1:0.5-about 1:2.5; for example, including but not limited to about 1:0.5, about 1:0.6, about 1:0.7, about 1:0.8, about 1:0.9, about 1:1, about 1:1.1, about 1:1.2, about 1:1.3, about 1:1.5, about 1:1.6, about 1:1.7, about 1:1.9, about 1:2, about 1:2.1, about 1:2.3, about 1:2.5, etc., and ranges consisting of any two of these ratios (values).
[0051] In one embodiment, the weight ratio of the first carrier material cyclodextrin to the second carrier material is about 1:1 to about 1:10, preferably about 1:1.5 to about 1:8, more preferably about 1:1 to about 1:3, for example about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, etc., and ranges consisting of any two of these ratios (values).
[0052] In one embodiment, the weight ratio of the active ingredient olaparib, the first carrier material cyclodextrin, and the second carrier material is about 1:0.5:0.5-about 1:2.0:3.0, preferably about 1:0.5:0.5-about 1:1.5:2.5, and more preferably about 1:0.5:0.5-about 1:1:2.2; for example, including but not limited to about 1:0.6:1.7, about 1:0.7:1.6, about 1:0.8:1.5, about 1:0.9:0.9, about 1:1:1, about 1:1.1:1.9, about 1:1.2:1.8, about 1:1.5:1.5, about 1:1.0:2, etc., and a range consisting of any two of these ratios (values).
[0053] In one embodiment, the total weight ratio of the active ingredient olaparib to the carrier material (i.e., the first carrier or the first carrier plus the second carrier) is about 1:0.5 to about 1:5, preferably about 1:0.5 to about 1:4, more preferably about 1:0.5 to about 1:3, for example, but not limited to about 1:0.6, about 1:0.7, about 1:0.8, about 1:0.9, about 1:1, about 1:1.1, about 1:1.2, about 1:1.3, about 1:1.4, about 1:1.5, about 1:1.6, about 1:1.7, about 1:1.8, about 1:1.9, about 1:2.0, about 1:2.1, about 1:2.2, about 1:2.3, about 1:2.4, about 1:2.5, about 1:2.6, about 1:2.7, about 1:2.8, about 1:2.9, about 1:3, etc., and ranges consisting of any two of these ratios (values).
[0054] In the embodiments of the present application, C% can be about 9%-50%, preferably about 11%-50%, more preferably about 29%-50%, for example, about 17%, about 20%, about 25%, about 33%, about 50%, etc., as well as a range consisting of any two of these ratios (values).
[0055] In one embodiment, Olaparib is dissolved in the carrier material or dispersed in the carrier material at a molecular level. It should be understood that the carrier material refers to the first carrier material or the first and second carrier materials (if present).
[0056] In another embodiment, the pharmaceutical composition may further include a solubilizing agent. The solubilizing agent is preferably D-α-tocopherol polyethylene glycol 1000succinate (also known as TPGS, Vitamin E TPGS or Tocophersolan). TPGS applicable to the present invention is a water-soluble derivative of vitamin E, which is esterified by the carboxyl group of vitamin E succinate (VES) and polyethylene glycol (PEG) 1000, and has a relative molecular weight of about 1513, which has been included in the United States Pharmacopoeia. TPGS not only acts as a solubilizing agent in the pharmaceutical composition and pharmaceutical preparation of the present invention, but also helps to improve bioavailability by affecting the efflux of the drug. Examples of available TPGS include BASF's commercially available product Kolliphor TM TPGS, but not limited to it.
[0057] In the pharmaceutical composition of the present invention, the amount of the solubilizer used is not particularly limited and can be adjusted according to actual conditions. Generally, the weight of the solubilizer is about 0.5-12% relative to the total weight of the active ingredient Olaparib, the first carrier material cyclodextrin and / or the second carrier material and TPGS, preferably about 7-11%.
[0058] In yet another aspect, the present invention also relates to a pharmaceutical preparation comprising the pharmaceutical composition of the present invention.
[0059] In one embodiment, the pharmaceutical preparation and / or pharmaceutical composition of the present invention may further include a pharmaceutically acceptable excipient. It should be understood by those skilled in the art that the pharmaceutically acceptable excipient used is used to assist in the preparation and improve the dosage form (such as stability, uniformity, etc.), and will not substantially change the properties of the pharmaceutical composition / preparation of the present invention, especially the active ingredients therein. Those skilled in the art can adjust the type and / or content of these excipients according to actual needs without affecting the properties of the pharmaceutical composition / preparation of the present invention.
[0060] In one embodiment, pharmaceutically acceptable excipients include, but are not limited to, one or more of glidants, surfactants, pH adjusters, diluents, disintegrants, binders, and lubricants.
[0061] As an example, the glidant may be one or more of colloidal silicon dioxide and talc.
[0062] As an example, the surfactant may be one or more of polyoxyethylene castor oil derivatives, polyoxyethylene glyceryl stearate, polyethylene glycol castor oil derivatives, block copolymers of ethylene oxide and propylene oxide, monofatty acid esters of polyoxyethylene (20) sorbitan, polyethylene glycol fatty acid esters, alkylene glycol fatty acid monoesters, and sorbitan fatty acid monoesters.
[0063] As an example, the pH adjuster may be one or more of citric acid, acetic acid, fumaric acid, maleic acid, tartaric acid, malic acid, succinic acid, oxalic acid, malonic acid, benzoic acid, mandelic acid and ascorbic acid, preferably one or more of citric acid.
[0064] As an example, the diluent may be one or more of microcrystalline cellulose, starch, pregelatinized starch, lactose, mannitol, and calcium hydrogen phosphate.
[0065] As an example, the disintegrant may be one or more of microcrystalline cellulose, carboxymethyl cellulose, crospovidone, croscarmellose sodium, carboxymethyl cellulose calcium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, hydroxymethyl starch, alginic acid, sodium alginate, guar gum, corn starch and magnesium aluminum silicate, preferably crosarmellose sodium.
[0066] As an example, the binder can be polyethylene glycol, starch, hydroxypropyl cellulose, hydroxypropyl methylcellulose, pregelatinized starch, polyvinyl pyrrolidone, gum arabic powder and gelatin, preferably one or more of starch, pregelatinized starch, modified starch, microcrystalline cellulose, silicified microcrystalline cellulose, low-substituted hydroxypropyl cellulose glucose, sucrose, lactose, sorbitol, mannitol, erythritol, calcium carbonate and calcium hydrogen phosphate, preferably one or more of mannitol, microcrystalline cellulose and silicified microcrystalline cellulose.
[0067] As an example, the lubricant can be one or more of magnesium stearate, stearic acid, stearate, sodium stearyl fumarate, sodium lauryl sulfate, polyethylene glycol, sodium benzoate, sucrose fatty acid esters, micronized silica, talc, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, stearic acid and hydrogenated vegetable oil.
[0068] It will be appreciated by those skilled in the art that the pharmaceutically acceptable adjuvants listed above are merely illustrative and representative. Therefore, the pharmaceutical preparation of the present invention is not limited to only comprising the pharmaceutically acceptable adjuvants listed above herein. Those skilled in the art may make various changes, adjustments or equivalent substitutions to the above adjuvants according to conventional techniques, all without exceeding the scope of protection of the present invention. It will also be appreciated by those skilled in the art that pharmaceutical compositions of the present invention may also include pharmaceutically acceptable adjuvants, such as those described above.
[0069] The pharmaceutical composition of the present invention can be further combined with pharmaceutically acceptable pharmaceutical excipients as needed to prepare various dosage forms. In one embodiment, the pharmaceutical preparation can be in the form of powder, granules, pills, capsules or tablets.
[0070] Preparation method of the present invention
[0071] In one embodiment of the present invention, there is also provided a method for preparing the pharmaceutical composition of the present invention, which comprises
[0072] 1) Providing the active ingredient olaparib and a carrier material;
[0073] 2) adding the material of step 1) into a hot melt extruder and extruding at about 120° C.-190° C.;
[0074] 3) Cooling, crushing and sieving the extrudate obtained in step 2) to obtain the pharmaceutical composition.
[0075] Optionally, the carrier material referred to in step 1) may include cyclodextrin, and may further include a second carrier material. Optionally, pharmaceutically acceptable pharmaceutical excipients may be added in step 1) and / or step 2). The addition of these materials may be carried out according to the desired stoichiometric ratio.
[0076] The temperature in step 2) can be 120-190° C., such as about 170-190° C., about 160-190° C., or 140-about 180° C. Optionally, the hot melt extruder can be preheated to the above temperature before or during the above method steps.
[0077] The hot melt extruder can be fed with a mixture of olaparib, a carrier material and an optional pharmaceutically acceptable pharmaceutical excipient (or a mixture of olaparib, a carrier material, TPGS and an optional pharmaceutically acceptable pharmaceutical excipient in a metered ratio), or a hot melt extruder can be directly fed with a metered ratio of olaparib, a carrier material and an optional pharmaceutically acceptable pharmaceutical excipient (or directly fed with olaparib, a carrier material, TPGS and an optional pharmaceutically acceptable pharmaceutical excipient). Extrusion is then performed, and the resulting extrudate is cooled, crushed and sieved, and optionally mixed with a pharmaceutically acceptable pharmaceutical excipient to obtain the pharmaceutical composition.
[0078] The cooling method used is not particularly limited and may include air cooling, water cooling, mechanical cooling, etc.
[0079] The type of extruder applicable to the present invention is not particularly limited, and includes but is not limited to single screw or twin screw hot melt extruder. In one embodiment, the extruder for preparing the pharmaceutical composition of the present invention is a twin screw extruder. In this case, there is no particular restriction on the type of screw rotation, and includes but is not limited to co-rotating twin screws, counter-rotating twin screws and double conical screw rotation modes.
[0080] In a preferred embodiment, the extruder used to prepare the pharmaceutical composition of the present invention is preferably a co-rotating twin-screw extruder. The temperature set for the hot melt extruder is about 160-about 190°C, and the screw speed is about 120-about 180rpm. The ratio of screw length to diameter (L / D) can be selected from about 25 to about 40. If the temperature of the hot melt extruder is too low, L / D is too short, and the screw speed is too slow, the heat and mechanical energy are insufficient during the hot melt process, and then Olaparib, the carrier material or TPGS cannot reach a molten state, or Olaparib cannot be dissolved in the molten carrier material. Therefore, although Olaparib and the carrier material are fully mixed, a single-phase solid dispersion (solid solution) in which Olaparib is dissolved in or dispersed in the carrier material at the molecular level cannot be obtained. If the temperature of the hot melt extruder is too high, the L / D is too long, and the screw speed is too fast, excessive thermal energy and mechanical energy are provided during the hot melt process. Even if a single-phase solid dispersion (solid solution) in which Olaparib is dissolved in or dispersed in the carrier material at the molecular level is obtained, it will cause unnecessary degradation of Olaparib and / or the carrier material and / or TPGS.
[0081] In other embodiments, the pharmaceutical composition of the present invention can be prepared by, for example, solution evaporation, spray drying, or coprecipitation, in addition to hot melt extrusion. These methods are also within the scope of the present invention.
[0082] Beneficial Effects
[0083] In one aspect, the present invention provides a pharmaceutical composition comprising olaparib, which increases the absorption and bioavailability of the active ingredient olaparib in the body, reduces the energy consumption of production, and improves production efficiency. In particular, in the pharmaceutical composition of the present invention, the active ingredient olaparib is dispersed in a cyclodextrin carrier material or a whole carrier material (including a second or other carrier material), which can improve the solubility of olaparib in the gastrointestinal tract, increase the absorption of olaparib in the body, and improve the bioavailability in the body.
[0084] On the other hand, the pharmaceutical composition of the present invention also has better production process characteristics, such as easy grinding, good compressibility, short disintegration time, etc., which reduces production energy consumption and improves production efficiency.
[0085] Furthermore, in the pharmaceutical composition of the present invention, the use of a combination of a first carrier material cyclodextrin and a second carrier material (e.g., polyethylene glycol / vinyl caprolactam / vinyl acetate copolymer such as Soluplus, and / or copolyvidone, such as Kollidon VA64 or Ashland Plasdone S630) as a mixed carrier material can further improve the solubility of Olaparib in the gastrointestinal tract, thereby further improving the absorption and bioavailability of Olaparib.
[0086] Furthermore, after adding polyethylene glycol 1000 vitamin E succinate (TPGS) to the pharmaceutical composition, the solubility of olaparib in the gastrointestinal tract can be further improved, thereby further increasing the absorption and bioavailability of olaparib. In addition, when the hot melt extrusion process of the present invention is used to prepare the pharmaceutical composition, the addition of TPGS can significantly reduce the hot melt extrusion operating temperature of the pharmaceutical composition, significantly reduce the torque, reduce energy consumption, and improve production capacity.
[0087] Example
[0088] Unless otherwise specified, the reagents and raw materials used herein are commercially available. For example, the Olaparib API (active ingredient) can be purchased from Taiwan Scino-Chemical, hydroxypropyl β-cyclodextrin can be purchased from Roquette, France, polyethylene glycol / vinyl caprolactam / vinyl acetate copolymer, TPGS can be purchased from BASF, and copolyvidone can be purchased from BASF or Ashland.
[0089] The determination methods used for evaluating the physicochemical properties in each embodiment are exemplified as follows:
[0090] 1. Glass transition temperature (Tg): Accurately weigh more than 3 mg of the test substance (such as olaparib raw material (hereinafter referred to as raw material), drug-loaded composition (i.e., the pharmaceutical composition of the present invention) or blank composition) for modulated differential scanning calorimetry analysis (mDSC, TA Q2000 differential scanning calorimeter) in the scanning temperature range of 40-180°C.
[0091] 2. Powder X-ray Diffraction (XRPD): Take an appropriate amount of the substance to be tested (raw material, drug-loaded composition or blank composition) and record the powder X-ray diffraction pattern under the conditions of Cu target, voltage 45 kV and current 45 mA (D8ADVANCE X-ray diffractometer manufactured by BRUKER).
[0092] 3. Apparent solubility: Weigh an excess of the olaparib pharmaceutical composition into a container, add a pH 6.8 phosphate buffer solution equivalent to approximately 2 / 3 of the container volume, and place the container in a shaker at 37°C for 2 hours. Filter the contents of the container with a 0.45 μm filter membrane, collect the filtrate, dilute with an appropriate amount of acetonitrile, and determine the olaparib concentration by HPLC analysis after vortex mixing. The HPLC analysis method is as follows:
[0093]
[0094] 4. Dissolution
[0095]
[0096] 5. Dissolution sample analysis method: the same as the HPLC analysis method described in the above apparent solubility determination.
[0097] Example 1 Olaparib-cyclodextrin pharmaceutical composition
[0098] 1. Preparation
[0099] The composition of the olaparib-cyclodextrin pharmaceutical composition and the dosage of each component are shown in Table 1-1.
[0100] Preparation method: Olaparib and carrier material cyclodextrin (hydroxypropyl β-cyclodextrin, Kleptose) and / or TPGS and other auxiliary ingredients are mixed directly or in a mixer and then fed into the hopper of a co-rotating twin-screw extruder (Omicron 12 of Steer Company, India) according to the dosage shown in Table 1-1. The temperature of the co-rotating twin-screw extruder is controlled between about 170 and about 190° C., and extrusion is performed at a screw speed of about 120 to about 170 rpm. The obtained extrudate is cooled, crushed, and sieved to obtain a pharmaceutical composition.
[0101] Table 1-1 Composition of Olaparib-cyclodextrin pharmaceutical composition and dosage of each component (weight %)
[0102]
[0103] 2. Evaluation of physical and chemical properties
[0104] 2.1. The glass transition temperature (Tg) of the pharmaceutical composition was determined
[0105] The test results are shown in Table 1-2.
[0106] Table 1-2 Glass transition temperature (Tg) test of olaparib-cyclodextrin pharmaceutical composition
[0107]
[0108] As can be seen from Table 1-2, the Tg values of the pharmaceutical compositions are significantly shifted compared with the Tg values of the corresponding blank compositions, and unlike the Tg value of the olaparib API (90.2°C), the melting peak of olaparib has disappeared. The above results clearly show that in each pharmaceutical composition of the present invention, olaparib is dissolved in the carrier material or dispersed in the carrier material at the molecular level, forming a molecularly dispersed solid dispersion (i.e., a glass solution).
[0109] 2.2. Apparent solubility determination of pharmaceutical compositions
[0110] The test results are shown in Tables 1-3.
[0111] Table 1-3 Apparent solubility of olaparib-cyclodextrin pharmaceutical composition in pH 6.8 buffer
[0112]
[0113] It can be seen from Tables 1-3 that Olaparib in each pharmaceutical composition of the present invention has an obvious solubilizing effect, indicating that cyclodextrin has a good solubilizing effect on Olaparib.
[0114] Adjusting the weight ratio of the drug substance (i.e., active ingredient) and the carrier material cyclodextrin (Kleptose) in the pharmaceutical composition from 1:1.8 (composition 1-1) to 1:5 (composition 1-6) can increase the apparent solubility from 0.42 mg / ml to 0.60 mg / ml. It can be seen that the change in apparent solubility is limited, which indicates that the weight ratio of the active ingredient to the carrier material cyclodextrin has little effect on the solubility of Olaparib, and when the carrier material is increased to a certain extent (composition 1-5 and composition 1-6), the solubility remains basically unchanged.
[0115] However, adding a small amount of TPGS (composition 1-3) to composition 1-2 can increase the apparent solubility from 0.47 mg / ml to 0.68 mg / ml, indicating that the pharmaceutical composition containing TPGS can also significantly improve the solubility of Olaparib while reducing the amount of carrier material.
[0116] 2.3 Dissolution Determination of Pharmaceutical Compositions
[0117] The main absorption site of drugs in the human body is the small intestine, and the pH value of the small intestine environment is about 6.8. According to the method described above, the solubility of each olaparib-cyclodextrin pharmaceutical composition in pH 6.8 phosphate buffer was determined, and the results are shown in Tables 1-4.
[0118] Table 1-4 Dissolution of Olaparib-Cyclodextrin Pharmaceutical Composition in pH 6.8 Phosphate Buffer
[0119]
[0120] From the data in the above table, it can be seen that the dissolution rate of the raw material drug within 2 hours is only 40.2%. Compared with the raw material drug, the dissolution rate of the pharmaceutical composition of the present invention in pH 6.8 phosphate buffer at the end point of 2 hours is higher than 85%, and the dissolution rate of all the pharmaceutical compositions of the present invention at various time points after 30 minutes is higher than 50%.
[0121] In particular, the dissolution of the olaparib-cyclodextrin pharmaceutical composition 1-3 containing TPGS at the end point 2h reached the highest 101.3%, which was significantly higher than the dissolution of the raw material drug, indicating that the pharmaceutical compositions of the present invention can significantly improve the absorption of olaparib in the body. In addition, the dissolution of the pharmaceutical compositions 1-3 at each time point after 30min was above 75%. This shows that in the pharmaceutical composition of the present invention, the absorption of olaparib in the body can be better improved by adding a solubilizer.
[0122] Example 2 Olaparib-(mixed) carrier pharmaceutical composition
[0123] 1. Preparation
[0124] The composition of the olaparib-(mixed) carrier pharmaceutical composition and the dosage of each component are shown in Table 2-1.
[0125] Preparation method: Olaparib and a carrier material (cyclodextrin (Kleptose) and / or a second carrier ( VA64)) and / or TPGS and other auxiliary ingredients are directly or uniformly mixed in a mixer and fed into a hopper of a co-rotating twin-screw extruder (Omicron 12 of Steer Company, India), and the temperature of the co-rotating twin-screw extruder is controlled between about 160 and about 190° C. for extrusion, and the screw speed is about 120 to about 180 rpm. The obtained extrudate is cooled, crushed, and sieved to obtain a pharmaceutical composition.
[0126] Table 2-1 Composition of Olaparib-(mixed) carrier pharmaceutical composition and amount of each component (weight %)
[0127]
[0128] 2. Evaluation of physical and chemical properties
[0129] 2.1. Determination of glass transition temperature (Tg)
[0130] The glass transition temperature test results of the olaparib-(mixed) carrier pharmaceutical composition are shown in Tables 2-2 and Figure 1 .in, Figure 1 The effect of the cyclodextrin (Kleptose) content in the pharmaceutical composition on the Tg value is shown. When the weight ratio of the API (i.e., active ingredient) to the (total) carrier material remains unchanged (e.g., API: carrier material = 1:2.3), when the proportion of cyclodextrin to the total carrier material is C% (cyclodextrin / (cyclodextrin + second carrier)%), it can be specifically calculated as Kleptose / (Kleptose + When VA64)% is 0%, 25%, 33%, 50% and 100%, they correspond to composition 2-1, composition 2-2, composition 2-3, composition 2-4 and composition 1-3, respectively. Figure 1 It can be seen that as the content of cyclodextrin Kleptose in the composition increases, the Tg value shows an upward trend, and it is significantly different from the Tg value of olaparib (90.2°C), and the melting peak of olaparib has disappeared. This shows that in each olaparib-(mixed) carrier pharmaceutical composition of the present invention, olaparib is dissolved in the carrier material or dispersed in the carrier material at the molecular level, thereby forming a molecularly dispersed solid dispersion (i.e., a glass solution).
[0131] Table 2-2 Glass transition temperature (Tg) test of olaparib-(mixed) carrier drug composition
[0132]
[0133] 2.2. Powder-X-ray diffraction characterization (XRPD pattern)
[0134] Figure 2Olaparib-cyclodextrin (Kleptose) and / or a second carrier ( VA64) are XRPD patterns of the pharmaceutical compositions prepared, from bottom to top, the XRPD patterns of the raw material, composition 2-1, composition 2-2, composition 2-3, composition 2-4 and composition 1-3. Figure 2 It can be seen that no crystal diffraction peak of Olaparib was found in the XRPD patterns of compositions 1-3 and 2-1 made of a single carrier material and compositions 2-2, 2-3 and 2-4 made of mixed carrier materials, which indicates that in the pharmaceutical composition of the present invention, Olaparib is dissolved in the carrier material or dispersed in the carrier material at the molecular level.
[0135] 2.3. Apparent solubility determination
[0136] Table 2-3 Apparent solubility of olaparib-(mixed) carrier drug composition in pH 6.8 buffer
[0137]
[0138] It can be seen from Table 2-3 that each pharmaceutical composition of the present invention has a significant solubilizing effect on Olaparib, among which composition 2-6 has the most significant improvement on the solubility of Olaparib.
[0139] On the one hand, the pharmaceutical composition prepared by mixing carrier materials can improve the solubility of olaparib within a certain range. For example, when the weight ratio of the raw material (i.e., active ingredient) and the (total) carrier material is kept unchanged (e.g., 1:2.3), the C% is adjusted from 100% (composition 1-3) to 50% (composition 2-4), and the apparent solubility increases from 0.68 mg / ml to 0.82 mg / ml; the C%% is further adjusted from 50% (composition 2-4) to 33% (composition 2-3), and the apparent solubility continues to increase from 0.82 mg / ml to 0.96 mg / ml; the C% is further adjusted from 33% (composition 2-3) to 25% (composition 2-2), and the apparent solubility is reduced from 0.96 mg / ml to 0.94 mg / ml, with no significant change; but the C% is further reduced to 0% (composition 2-1), and the apparent solubility is reduced to 0.63 mg / ml. This indicates that the pharmaceutical composition prepared by mixing carrier materials can improve the solubility of Olaparib within a certain range.
[0140] On the other hand, mixed carrier materials can significantly improve the apparent solubility of Olaparib. For example, when the C% in the mixed carrier material is kept unchanged (e.g., 33%), the weight ratio of the API (i.e., active ingredient) and the (total) carrier material is adjusted from 1:1.8 (composition 2-5) to 1:2.3 (composition 2-3) and 1:3 (composition 2-6), the apparent solubility of the pharmaceutical composition is at least 7, 9, and 10 times higher than that of the API, respectively, and both are higher than the apparent solubility of the composition with a single carrier material, i.e., only containing a single carrier cyclodextrin (Kleptose) (composition 1-3) and only containing a single second carrier (VA64) (composition 2-1). This shows that, compared with the use of a single carrier material, the use of a mixed carrier material can significantly improve the apparent solubility of Olaparib, and further improve its absorption in the body, i.e., bioavailability. For example, when the C% in the mixed carrier material is 33%, the corresponding compositions (ie, composition 2-3, composition 2-5 and composition 2-6) all have a significant solubilization effect on Olaparib.
[0141] Dissolution assay
[0142] Table 2-4 Dissolution of Olaparib-(mixed) carrier drug composition in pH 6.8 phosphate buffer
[0143]
[0144] The dissolution curves of composition 2-3 and the raw material drug are as follows Figure 3 As shown in Table 2-4 and Figure 3 It can be seen that the dissolution rate of the raw material drug in pH 6.8 within 2 hours is about 40%.
[0145] Compared with API:
[0146] 1) The solubility of the pharmaceutical compositions of the present invention at pH 6.8 within 2 hours was significantly improved, wherein the solubility of compositions 2-2 to 2-6 at each time point after 30 minutes was above 85%, indicating that they can significantly improve the absorption of olaparib in the body.
[0147] 2) The dissolution rates of compositions 2-2 to 2-6 made of mixed carrier materials are higher than those of compositions 2-1 and 1-3 made of single carrier materials. Therefore, the overall absorption rate of compositions 2-2 to 2-6 made of mixed carrier materials in the body is better than that of compositions 2-1 and 1-3.
[0148] Figure 4The figure shows the effect of the cyclodextrin content in the pharmaceutical composition made of olaparib-(mixed) carrier (the weight ratio of olaparib to carrier material is 1:2.3) on the dissolution of olaparib in pH 6.8, wherein the dissolution curves when C% is 0%, 25%, 33%, 50% and 100% correspond to the dissolution curves of composition 2-1, composition 2-2, composition 2-3, composition 2-4 and composition 1-3, respectively. Figure 4 It can be seen that at pH 6.8, the solubility of the compositions composed of mixed carrier materials is improved compared with compositions 2-1 and 1-3 made of a single carrier material. When C% is 25% and 33%, respectively, the solubility of the corresponding compositions 2-2 and 2-3 made of mixed carrier materials is improved most significantly. The solubility of these two compositions at pH 6.8 is significantly better than that of the compositions containing only the second carrier ( Composition 2-1 containing VA64) and composition 1-3 containing only cyclodextrin (Kleptose).
[0149] Example 3 Olaparib-(mixed) carrier pharmaceutical composition
[0150] 1. Preparation
[0151] The combination and dosage of each component of the olaparib-(mixed) carrier pharmaceutical composition are shown in Table 3-1.
[0152] Table 3-1 Composition of Olaparib-(mixed) carrier pharmaceutical composition and amount of each component (weight %)
[0153]
[0154] Preparation method: Olaparib and mixed carrier material ( and Kleptose) and other auxiliary ingredients are directly or evenly mixed in a mixer and then fed into the hopper of a co-rotating twin-screw extruder (Omicron 12 of Steer Company, India), and the temperature of the co-rotating twin-screw extruder is controlled between about 140-about 180°C for extrusion, and the screw speed is about 110-about 180rpm. The obtained extrudate is cooled, crushed, and sieved to obtain a solid powder. Then, other pharmaceutical excipients and the solid powder are evenly mixed according to the amounts shown in Table 3-1 to obtain an Olaparib pharmaceutical composition.
[0155] 2. Evaluation of physical and chemical properties
[0156] 2.1. Apparent solubility determination of drug compositions
[0157] Table 3-2 Apparent solubility of olaparib-(mixed) carrier drug composition in pH 6.8 buffer
[0158]
[0159] As can be seen from Table 3-2, the olaparib mixed carrier pharmaceutical composition can significantly improve the apparent solubility of olaparib, and is superior to the composition containing only a single carrier material. For example, when the weight ratio of the raw material and the mixed carrier material is kept unchanged (for example, 1:3), each olaparib-(mixed) carrier pharmaceutical composition (3-3, 3-5, 3-6) can significantly improve the apparent solubility of olaparib, and is superior to the composition 3-1 containing only a single carrier material, among which the improvement of composition 3-3 is the most obvious. This shows that compared with the use of a single carrier material, the use of a mixed carrier material can significantly improve the apparent solubility of olaparib, and can further improve its absorption in the body.
[0160] On the other hand, the addition of a solubilizer can improve solubility. For example, when the weight ratio of the drug substance to the carrier material is kept unchanged (e.g., 1:3), after a small amount of TPGS is added to composition 3-1 and composition 3-3 (corresponding to composition 3-2 and composition 3-4), the apparent solubility increases from 0.52 mg / ml and 0.72 mg / ml to 0.74 mg / ml and 0.87 mg / ml, respectively. This shows that the pharmaceutical composition containing a solubilizer can further improve the absorption of Olaparib in the body.
[0161] 2.2. Dissolution Determination of Pharmaceutical Compositions
[0162] Table 3-3 Dissolution of the pharmaceutical composition in pH 6.8 phosphate buffer
[0163]
[0164] As shown in Table 3-3, compared with the raw material drug:
[0165] 1) The dissolution rate of the pharmaceutical composition of the present invention in pH 6.8 within 2 hours was significantly improved, among which the improvement of composition 3-4 was the most obvious, and the dissolution rate at each time point after 30 minutes was above 90%, and the dissolution rate of composition 3-3 and composition 3-4 made of mixed carrier materials was higher than that of the corresponding composition 3-1 and composition 3-2 made of single carrier materials. This shows that the use of mixed carrier materials can significantly improve the solubility of olaparib compared with single carrier materials, and further improve the absorption of olaparib in the body;
[0166] 2) The solubility of the pharmaceutical compositions 3-2 and 3-4 containing TPGS were higher than that of the compositions 3-1 and 3-3 not containing TPGS, indicating that the solubilizer can further improve the solubility of Olaparib and further improve the absorption of Olaparib in the body.
[0167] Example 4 Evaluation of the preparation method of mixed carrier pharmaceutical composition
[0168] 1. Hot melt extrusion process
[0169] Table 4-1 Hot melt extrusion process parameters
[0170]
[0171] The process flow is shown in the preparation of each pharmaceutical composition in Examples 1-3, and the specific parameters are shown in Table 4-1.
[0172] As shown in Table 4-1, with a single second carrier material ( Compared with composition 2-1 made of cyclodextrin carrier material (VIA64), composition 1-3 made of a single cyclodextrin carrier material (Kleptose) has lower energy consumption per kilogram and produces a lower percentage of torque.
[0173] The glass transition temperatures of compositions 2-2, 2-3 and 2-4 made of mixed carrier materials are all higher than those of composition 2-1 made of a single carrier material, and are significantly different from the Tg value of olaparib, which indicates that olaparib forms a glass solution with the carrier material, and the viscosity of the mixture of prescription components using the mixed carrier is relatively lower, and the screw speed during the process is reduced. Correspondingly, the energy consumption per kilogram of compositions 2-2, 2-3 and 2-4 made of mixed carrier materials is lower. The percentage of torque generated is also lower, which indicates that the use of mixed carrier materials to prepare pharmaceutical compositions can significantly reduce the energy consumption and instrument torque of the hot melt extrusion process, greatly improving its operability.
[0174] 2. Crushing process
[0175] Table 4-2 Extrudate crushing process parameters
[0176]
[0177] The extrudates obtained from the preparation of each pharmaceutical composition were cut into strips of about 2 cm with scissors and pulverized at 4000 rpm for 60 seconds using a Fitzmill pulverizer (model: RP-L1A). The pulverized particles were sieved through a 60-mesh sieve, and the weight of the powder obtained after sun exposure was weighed to calculate the pulverization yield.
[0178] As shown in Table 4-2, with a single second carrier material ( Compared with the sieving efficiency (40.5%) of composition 2-1 made of VA64), the sieving efficiency of the pharmaceutical composition made of mixed carrier materials or single cyclodextrin carrier material is higher (higher than 67%), indicating that the operability of its pulverization process is stronger.
[0179] Example 5 In vivo pharmacokinetic study of olaparib-mixed carrier pharmaceutical composition
[0180] The study was conducted in humans using an open, randomized, two-period, double-crossover, self-controlled pharmacokinetic comparison trial under fasting conditions.
[0181] The 10 selected healthy subjects were randomly divided into 2 groups: Group 1 and Group 2, with 5 people in each group. Group 1 first orally took the tablets containing the composition 2-1 prepared in Example 5, and Group 2 first orally took the tablets containing the composition 2-3 prepared in Example 5. After a 1-week washout period, a crossover test was performed. The grouping scheme is shown in the following table:
[0182] Table 5-1 Grouping
[0183]
[0184] 4 mL of cubital venous blood was collected at 0h, 0.25h, 0.5h, 1.0h, 1.5h, 2.0h, 2.5h, 3.0h, 3.5h, 4.0h, 5.0h, 7.0h, 9.0h, 12.0h, 24.0h, and 48.0h (a total of 16 blood collection points) after taking the medicine, and then centrifuged to extract and separate plasma, and stored in a -20℃ refrigerator for testing.
[0185] The concentration of olaparib in each plasma sample was determined by LC-MS / MS method, and the biostatistical analysis was completed by calculation using pharmacokinetic statistical software WinNonlin v6.4. The test results are shown in Table 5-2 and Figure 5 .
[0186] Table 5-2 Geometric mean statistics of olaparib pharmacokinetic parameters (n=10)
[0187]
[0188] from Figure 5 As shown in Table 5-1, compared with using a single second carrier material ( VA64) compared to the composition 2-1, the use of mixed carrier material ( The olaparib in the composition 2-3 of VA64) is absorbed faster in the body, has a higher blood concentration, and correspondingly has a higher bioavailability. max The geometric mean ratio (composition 2-3 / composition 2-1) was 1.27; AUC 0-48h and AUC0 0-∞ The geometric mean ratios of (Composition 2-3 / Composition 2-1) were 1.25 and 1.23, respectively.
[0189] In summary, the olaparib composition prepared by using a mixed carrier material has significantly improved in vitro solubility and dissolution rate compared with the olaparib composition prepared by using a single carrier material, and the in vivo Cmax , the overall bioavailability has also been improved.
[0190] Those skilled in the art will appreciate that the above specific implementations in the form of embodiments are used to further describe the above contents of the present invention. However, this should not be construed as limiting the scope of the subject matter of the present invention to the above embodiments. All solutions implemented based on the above contents of the present invention are within the scope of the present invention.
Claims
1. A pharmaceutical composition comprising an active ingredient, olaparib, and a carrier material, cyclodextrin, characterized in that: The carrier material cyclodextrin is hydroxypropyl beta-cyclodextrin; The pharmaceutical composition further comprises a second carrier material, wherein the second carrier material is copovidone; The weight ratio of the carrier material cyclodextrin to the second carrier material is 1:2-1:3; The weight ratio of the active ingredient Olaparib to the sum of the carrier material cyclodextrin and the second carrier material is 1:2.3-1:2.9; The pharmaceutical composition further comprises a solubilizer, which is polyethylene glycol 1000 vitamin E succinate; The weight ratio of the solubilizer to the total weight of the active ingredient Olaparib, the carrier material cyclodextrin, the second carrier material and the solubilizer is 7-11%; The active ingredient Olaparib is dissolved in the carrier material cyclodextrin and the second carrier material or dispersed in the carrier material cyclodextrin and the second carrier material at a molecular level.
2. The pharmaceutical composition according to claim 1, characterized in that The weight ratio of the active ingredient Olaparib to the carrier material cyclodextrin is 1:0.6-1:
1.
3. The pharmaceutical composition according to claim 1, characterized in that The weight ratio of the active ingredient Olaparib to the second carrier material is 1:1.5-1:1.
9.
4. A solid pharmaceutical preparation comprising the pharmaceutical composition according to any one of claims 1 to 3.
5. The solid pharmaceutical preparation according to claim 4, characterized in that The pharmaceutical preparation is in the form of powder, granules, pills, capsules or tablets.
6. The solid pharmaceutical preparation according to claim 4, characterized in that The pharmaceutical preparation further comprises pharmaceutically acceptable excipients.
7. The solid pharmaceutical preparation according to claim 6, characterized in that The auxiliary material is one or more of a glidant, a diluent, a disintegrant, a binder, and a lubricant.
8. Use of the pharmaceutical composition according to any one of claims 1 to 3 or the pharmaceutical preparation according to any one of claims 4 to 7 in the preparation of a drug for treating malignant tumors, characterized in that: The malignant tumor is ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, non-small cell lung cancer, esophageal cancer or gastric cancer.
9. A method for preparing the pharmaceutical composition of any one of claims 1 to 3, comprising: 1) providing an active ingredient olaparib, a carrier material cyclodextrin, a second carrier material copovidone, and a solubilizer polyethylene glycol 1000 vitamin E succinate; 2) adding the material of step 1) into a hot melt extruder and extruding at 120° C.-190° C.; 3) Cooling, crushing and sieving the extrudate obtained in step 2) to obtain the pharmaceutical composition.
Citation Information
Patent Citations
Pharmaceutical formulation 514
CN102238945A
Olaparib solid dispersion preparation and preparation method thereof
CN104434809A
Preparation method of olaparib solid dispersoid and product thereof
CN106692066A
Olaparib pharmaceutical composition and preparation method thereof
CN106137998A
Olaparib oral controlled-release and sustained-release pharmaceutical composition and uses thereof
CN108201536A
Cited By
Olaparib pharmaceutical composition, preparation thereof, preparation method therefor and use thereof
WO2021164755A1
